SYNLAB International

What SYNLAB International does

SYNLAB International GmbH is a Munich-headquartered, privately held medical diagnostic services provider operating across more than 20 countries on four continents. The company offers a portfolio of over 5,000 routine and specialty testing services, including clinical biochemistry, haematology, medical imaging, and an expanding specialty genetics franchise (myPGx pharmacogenetics, the 25-gene BRCAPlus hereditary cancer panel, and Familial Hypercholesterolaemia testing), processed through a network of more than 300 laboratories, 1,800+ blood collection points, and 23,000+ employees including over 2,000 medical experts. SYNLAB reported EUR 2.54 billion of revenue in 2025 and performs approximately 600 million laboratory tests annually.

Revenue is generated through a sales-led, multi-channel model that combines physician and hospital referrals, direct-to-patient testing at physical lab and blood collection locations, government and public health screening contracts, and corporate occupational health programs. Pricing is not publicly disclosed and is driven by negotiated B2B agreements, regional reimbursement frameworks, and test type. The customer base spans patients and individuals, practicing doctors, hospitals and clinics, governments, and corporations, which diversifies revenue across both clinical and enterprise channels and across Europe, Latin America, Africa, the Middle East, and Mexico.

Technology differentiation centers on a proprietary next-generation sequencing (NGS) bioinformatics pipeline, AI-augmented variant classification (via integration with the Franklin Decision Support platform in the UK), and computer vision for syndromic facial analysis. The company is owned by Cinven, which acquired it in a private equity roll-up strategy that has included deals such as the 2021 Gruppo Tronchet acquisition in Italy and the 2013 Medicap Holding acquisition. SYNLAB also operates the SYNLAB Foundation, a Munich-based gGmbH focused on early disease detection and healthcare access.

Name

SYNLAB International

Legal name

SYNLAB International GmbH

Website

https://synlab.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

SYNLAB International is a Munich-based, Cinven-owned medical diagnostics provider operating 300+ laboratories and 1,800+ blood collection points across 20+ countries, offering over 5,000 routine and specialty tests to patients, physicians, hospitals, governments, and corporations.

Ownership category

akta.pro rank

Product category

Medical Diagnostic Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), Services-Misc Health & Allied Services, Nec (8090), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Central Laboratory Services (Core Lab Operations) (HLAGAEAA)

akta.pro secondary industries

Reference & Esoteric Testing Laboratories (HLAFAMAJ), Clinical Research & Trial Central Laboratories (HLAFAMAL), Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)

Keywords

• Medical laboratory diagnostics
• Clinical diagnostic services
• Human health testing
• Veterinary diagnostics
• Environmental analytical services

Headquarters

HQ city

Augsburg

HQ country

Germany

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Laboratory Diagnostic Services: SYNLAB generates revenue primarily through providing medical diagnostic testing services to patients, healthcare providers, hospitals, clinics, governments, and corporations across their network of 300+ laboratories and 1,800+ blood collection points.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

SYNLAB International is a medical diagnostics service provider operating one of the largest networks of clinical laboratories in Europe, delivering a broad portfolio of routine and specialty diagnostic tests for human and veterinary medicine as well as environmental analysis. The company operates more than 300 laboratories and 1,800 blood collection points across more than 20 countries on four continents, processing approximately 600 million tests per year for healthcare providers, organisations, and individual patients.

Product overview

SYNLAB International is Europe's leading medical diagnostic services provider offering a comprehensive portfolio spanning routine and specialty testing. The portfolio includes core diagnostic services (clinical biochemistry, haematology, medical imaging) combined with specialized offerings (genetic testing services including myPGx pharmacogenetics, BRCAPlus hereditary cancer testing, and Familial Hypercholesterolaemia testing). The company operates over 300 laboratories and more than 1,800 blood collection points across 20+ countries, providing over 5,000 routine and specialty testing services. SYNLAB's genetics services feature AI-powered analysis including facial analysis for syndrome identification and variant classification, supported by a network of over 2,000 medical experts contributing to advancing medical knowledge through peer-reviewed research.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Biochemistry
• Haematology
• Medical Imaging
• Genetic Testing Services
• myPGx (Pharmacogenetics)
• BRCAPlus
• Familial Hypercholesterolaemia (FH) Genetic Testing
• Pre-Implantation Genetic Testing (PGT)
• Veterinary Diagnostic Services
• Environmental Analysis Services

Quantifiable outcome

• Over 65% of clinical decision-making is based on laboratory testing
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability6 records

Feature5 records

Scale indicators8 records

Recent moves6 records

Expansion highlights8 records

Broad incumbents

• Quest Diagnostics: US-listed clinical laboratory giant offering routine and advanced diagnostics; competes with SYNLAB globally, especially for clinical trial central lab services and reference testing.
• Laboratory Corporation of America (Labcorp): One of the world's largest clinical laboratory networks, offering routine and esoteric diagnostics plus central lab services for clinical trials, overlapping materially with SYNLAB's portfolio.
• Eurofins Scientific: Large international bioanalytical and clinical diagnostics testing group with overlapping laboratory testing capabilities, especially in clinical and specialty diagnostics across European markets.
• Sonic Healthcare: Global medical diagnostics operator with significant European and Australian laboratory networks, providing comparable routine and specialty testing services at greater geographic scale.

Direct peers

• Synnovis (Guy's and St Thomas' NHS partnership): SYNLAB's UK pathology joint venture operating hospital laboratories and pathology services for major NHS trusts, directly comparable in business model and customer base.
• Unilabs: Major European clinical diagnostics and reference laboratory operator also owned by Cinven, offering a directly overlapping portfolio of routine and specialty testing services across multiple European countries.
• Cerba Healthcare: European clinical pathology and central laboratory services provider serving hospitals and clinicians with routine and specialty diagnostics, directly comparable to SYNLAB's core central lab business.

Emerging players

• Medicover: European healthcare and diagnostics provider operating clinical laboratories across Central and Eastern Europe, competing for regional share against SYNLAB's Eastern European footprint.
• Bioniq Health-Tech / regional genetic labs: European emerging players focused on consumer and clinical-grade genetic and specialty testing, competing for high-margin specialty volumes that SYNLAB targets with myPGx and BRCAPlus.

Regional players

• LADR Laborverbund Dr. Kramer & Kollegen: German regional laboratory network offering medical diagnostics to physicians and hospitals, directly competing with SYNLAB's largest single market (Germany).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/synlab-international

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries26 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SYNLAB International